· Issued by Cardiol Therapeutics Inc. Class A via CNW
Cardiol Therapeutics Inc. Closes the Market
Canada NewsWire
TORONTO, Jan. 25, 2019
TORONTO, Jan. 25, 2019 /CNW/ - David Elsley, President & CEO, Cardiol Therapeutics Inc. (CRDL), joined Loui Anastasopoulos, President, Capital Formation, Toronto Stock Exchange & TSX Venture Exchange, to close the market. Cardiol Therapeutics is a biotechnology company specializing in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. Cardiol Therapeutics Inc. commenced trading on Toronto Stock Exchange on December 20, 2018.
